Advancing Oncology Innovation: Celebrating One Year of Pfizer + Seagen

Pfizer has a longstanding commitment to advancing innovative cancer treatments to help improve outcomes for patients worldwide. One year ago, Pfizer’s acquisition of Seagen Inc., one of the largest investments in Pfizer’s history, marked a bold step in the company’s plans to “Outdo” cancer, bringing together Pfizer’s global scale and Seagen’s leadership in antibody-drug conjugate (ADC) technology. This collaboration has already begun yielding significant advancements in Oncology, strengthening Pfizer’s position as a leader in delivering transformative cancer medicines.

Working to Achieve World-Class Oncology Leadership

In the first half of 2024, the company became the third largest biopharma company in Oncology in the United States by revenue. Pfizer’s industry-leading portfolio and extensive pipeline includes three core mechanisms of action to treat cancer from multiple angles, including small molecules, ADCs and bispecific antibodies, including other immune-oncology biologics. Pfizer is focused on delivering transformative therapies in some of the world’s most common cancers: breast cancer, across hormonal subtypes; genitourinary cancer, including prostate and bladder cancer; hematology-oncology, including multiple myeloma and lymphomas, such as Hodgkin’s disease; and thoracic cancers, which includes lung cancer.

Since acquiring Seagen, Pfizer has achieved several notable milestones accelerating new standards of care for cancer patients. Year-to-date, Pfizer Oncology has demonstrated new Phase 3 results for its therapies to potentially treat certain individuals with various forms of prostate cancer, blood cancer, breast cancer and non-small cell lung cancer. Pfizer’s pipeline has had positive early-stage readouts and/or advanced into late-stage clinical trials since the acquisition. Notably, Pfizer presented promising new and updated data for investigational ADCs for thoracic cancer and bladder cancer, as well as a potential first-in-class KAT6 inhibitor in breast cancer. The company also initiated new pivotal trials for treatments targeting various forms of breast cancer, lung cancer, blood cancer and prostate cancer.

A list of Pfizer’s Oncology pipeline candidates as of October 29, 2024 can be found here.

A Shared Vision for the Future

Pfizer retained many colleagues at legacy Seagen, more than 2,500 colleagues across its Oncology organization, including major research and development sites in Bothell, Washington and La Jolla, California, creating one of the most experienced oncology teams in the industry. Through an established and dedicated Oncology organization, Pfizer colleagues and scientists are moving with urgency to unlock potential novel combinations and next-generation biologics across a range of cancers to extend and improve patients’ lives.

Pfizer believes it is well positioned to fulfill its 2030 Oncology goal of delivering potentially 8 or more blockbuster medicines. Looking ahead, the company will remain focused on advancing therapies through a robust pipeline of over 50 Oncology clinical programs across various stages of development.

“We believe Oncology will be a significant growth driver for Pfizer and contribute meaningfully to the achievement of our near- and long-term financial goals,” said Dr. Albert Bourla, Pfizer Chairman and Chief Executive Officer.

The one-year anniversary of this acquisition is not just a celebration but a testament to the power of coming together to tackle the world’s most challenging diseases. Pfizer is reimagining the future of cancer, striving for a world where people with cancer live better and longer lives.